Render Target: SSR
Render Timestamp: 2024-11-14T22:45:52.497Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:57:31.411
Product last modified at: 2024-10-30T12:15:16.051Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77

FXR/NR1H4 (E4B8P) Mouse mAb #72105

Filter:
  • WB
  • IP
  • ChIP

    Supporting Data

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa) 55
    Source/Isotype Mouse IgG2a
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • ChIP-Chromatin Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Product Usage Information

    For optimal ChIP results, use 10 μl of antibody and 10 μg of chromatin (approximately 4 × 106 cells) per IP. This antibody has been validated using SimpleChIP® Enzymatic Chromatin IP Kits.

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:200
    Chromatin IP 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    FXR/NR1H4 (E4B8P) Mouse mAb recognizes endogenous levels of total FXR/NR1H4 protein.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human FXR/NR1H4 protein.

    Background

    The farnesoid X receptor (FXR/NR1H4) is a member of the nuclear hormone receptor superfamily and is a master regulator of bile acid synthesis. FXR/NR1H4 heterodimerizes with RXR-alpha upon activation by bile acids, which begins a regulatory cascade involving SHP and LRH-1 to control lipid homeostasis (1-5). FXR/NR1H4 has also been shown to be a critical regulator of glucose homeostasis (6,7). In addition to directly regulating genes, FXR/NR1H4 also plays a post transcriptional role in bile acid metabolism by transcribing the RNA-binding protein ZFP36L1, which in turn downregulates the key enzyme Cyp7a1 (8). Mutations in human FXR/NR1H4 have been shown to cause cholestasis and liver disease in neonatal patients (9). FXR/NR1H4 can also control Lgr5+ intestinal stem cell proliferation and its upregulation has been shown to inhibit colorectal cancer progression (10-12). Agonists against FXR/NR1H4 are being evaluated for various liver diseases and diabetes (13-16).
    1. Parks, D.J. et al. (1999) Science 284, 1365-8.
    2. Wang, H. et al. (1999) Mol Cell 3, 543-53.
    3. Laffitte, B.A. et al. (2000) J Biol Chem 275, 10638-47.
    4. Edwards, P.A. et al. (2002) J Lipid Res 43, 2-12.
    5. Goodwin, B. et al. (2000) Mol Cell 6, 517-26.
    6. Ma, K. et al. (2006) J Clin Invest 116, 1102-9.
    7. Zhang, Y. et al. (2006) Proc Natl Acad Sci U S A 103, 1006-11.
    8. Tarling, E.J. et al. (2017) J Clin Invest 127, 3741-54.
    9. Gomez-Ospina, N. et al. (2016) Nat Commun 7, 10713.
    10. Modica, S. et al. (2008) Cancer Res 68, 9589-94.
    11. Fu, T. et al. (2019) Cell 176, 1098-1112.e18.
    12. Qiao, P. et al. (2018) Oncol Rep 40, 2067-78.
    13. Pellicciari, R. et al. (2002) J Med Chem 45, 3569-72.
    14. Hirschfield, G.M. et al. (2015) Gastroenterology 148, 751-61.e8.
    15. Neuschwander-Tetri, B.A. et al. (2015) Lancet 385, 956-65.
    16. Genin, M.J. et al. (2015) J Med Chem 58, 9768-72.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    CST is a registered trademark of Cell Signaling Technology, Inc.
    SimpleChIP is a registered trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.